MX2007004973A - Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. - Google Patents
Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.Info
- Publication number
- MX2007004973A MX2007004973A MX2007004973A MX2007004973A MX2007004973A MX 2007004973 A MX2007004973 A MX 2007004973A MX 2007004973 A MX2007004973 A MX 2007004973A MX 2007004973 A MX2007004973 A MX 2007004973A MX 2007004973 A MX2007004973 A MX 2007004973A
- Authority
- MX
- Mexico
- Prior art keywords
- water
- soluble
- solubility
- solid
- chemical substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invencion se refiere a una formulacion solida con solubilidad mejorada y estabilidad mantenida incluyendo una sustancia quimica poco soluble en agua como un ingrediente farmaceuticamente activo formulado de una manera mejorada; de manera mas especifica, la presente invencion se refiere a una formulacion solida que tiene solubilidad en agua mejorada que comprende una sustancia quimica poco soluble en agua como un ingrediente farmaceuticamente activo, una sustancia de polimero soluble en agua y una sustancia porosa inorganica, caracterizada porque (1) la sustancia quimica poco soluble en agua forma una dispersion solida junto con la sustancia de polimero soluble en agua, (2) la sustancia de polimero soluble en agua que forma las dispersiones solidas esta en forma de piezas pequenas, y (3) la sustancia de polimero soluble en agua que esta en forma de piezas pequenas se mantiene para ser adsorbida en y/o adherida a la superficie de la sustancia porosa inorganica; la formulacion solida se puede producir agitando y mezclando una solucion obtenida disolviendo una sustancia quimica poco soluble en agua como un ingrediente farmaceuticamente activo y una sustancia de polimero soluble en agua en un solvente organico con una sustancia porosa inorganica y despues granulando y secando la mezcla.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004310254 | 2004-10-25 | ||
US63189404P | 2004-11-30 | 2004-11-30 | |
PCT/JP2005/019744 WO2006046623A1 (ja) | 2004-10-25 | 2005-10-20 | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007004973A true MX2007004973A (es) | 2007-06-14 |
Family
ID=36227865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007004973A MX2007004973A (es) | 2004-10-25 | 2005-10-20 | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060153913A1 (es) |
EP (1) | EP1806149A4 (es) |
KR (1) | KR20070072888A (es) |
AU (1) | AU2005297923B2 (es) |
BR (1) | BRPI0516772A (es) |
CA (1) | CA2582767C (es) |
MX (1) | MX2007004973A (es) |
RU (1) | RU2375046C2 (es) |
WO (1) | WO2006046623A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG165154A1 (en) | 2002-02-28 | 2010-10-28 | Japan Tobacco Inc | Ester compound and medical use thereof |
EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
JP5697296B2 (ja) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
WO2006100875A1 (ja) * | 2005-03-24 | 2006-09-28 | Daiichi Sankyo Company, Limited | 医薬用組成物 |
US20090068281A1 (en) * | 2005-03-29 | 2009-03-12 | Koji Toyomura | Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity |
EP1951224A2 (en) * | 2005-10-18 | 2008-08-06 | Aegerion Pharmaceuticals | Methods for treating disorders associated with hyperlipidemia in a mammal |
US20080051427A1 (en) * | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
KR101667534B1 (ko) * | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
AU2007339080B2 (en) * | 2006-12-22 | 2012-09-27 | Yuhan Corporation | Revaprazan-containing solid dispersion and process for the preparation thereof |
EP1997480A1 (en) * | 2007-06-01 | 2008-12-03 | The Jordanian Pharmaceutical Manufacturing Co. | Mineral-fiber solid dispersion, method for preparing the same and use thereof as pharmaceutical tableting aid |
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
WO2010092925A1 (ja) * | 2009-02-12 | 2010-08-19 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
CA2759125C (en) * | 2009-04-24 | 2017-08-15 | Iceutica Pty Ltd | A novel formulation of indomethacin |
US9023398B2 (en) | 2009-09-30 | 2015-05-05 | Kabushiki Kaisha Sangi | Method for improving the aqueous solubility of poorly-soluble substances |
WO2012049566A1 (en) | 2010-10-14 | 2012-04-19 | Japan Tobacco Inc. | Combination therapy for use in treating diabetes |
KR101739818B1 (ko) * | 2011-05-20 | 2017-05-26 | 주식회사유한양행 | 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물 |
AU2012295397A1 (en) * | 2011-08-16 | 2014-02-20 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
JP5909796B2 (ja) | 2012-03-02 | 2016-04-27 | 株式会社サンギ | 難溶性物質の水溶解性改善方法 |
KR101986683B1 (ko) * | 2012-12-13 | 2019-06-10 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
CN104271134B (zh) * | 2013-01-15 | 2016-06-29 | 富士胶片株式会社 | 含有5-羟基-1h-咪唑-4-甲酰胺的片剂 |
JP6344678B2 (ja) * | 2013-09-27 | 2018-06-20 | キョーリンリメディオ株式会社 | テルミサルタン含有製剤及びその製造方法 |
WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
WO2017140253A1 (zh) * | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
KR20240032149A (ko) | 2017-03-03 | 2024-03-08 | 인스피르나, 인크. | 향상된 안정성을 갖는 제제 |
CN111039984B (zh) * | 2018-10-15 | 2022-06-07 | 上海盟科药业股份有限公司 | 康泰唑胺酯的药物晶体及其制备方法和应用 |
JP7260353B2 (ja) * | 2019-03-25 | 2023-04-18 | 株式会社ファンケル | コエンザイムq10の固体分散体 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
JPS57206612A (en) * | 1982-04-16 | 1982-12-18 | Bayer Ag | Collapsible absorptive compressed mold article of hard soluble medicine |
GB8925833D0 (en) * | 1989-11-15 | 1990-01-04 | Robertet Sa | Derivatives of aromatic benzoates as inhibitors of esterase-producing micro-organisms |
JPH0597672A (ja) * | 1991-10-08 | 1993-04-20 | Terumo Corp | アミド誘導体含有固形製剤およびその製造方法 |
JPH0597682A (ja) * | 1991-10-14 | 1993-04-20 | Meiji Seika Kaisha Ltd | 制ガン作用を有する高分子化合物 |
US5916593A (en) * | 1994-09-22 | 1999-06-29 | Akzo Nobel, N.V. | Process of making dosage units by wet granulation |
DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
PT893999E (pt) * | 1996-03-18 | 2002-12-31 | Nissan Chemical Ind Ltd | Processo para a producao para a producao de preparacoes de cloridrato de efonidipina |
US6057339A (en) * | 1996-05-09 | 2000-05-02 | Bristol-Myers Squibb Company | Method of inhibiting or treating phytosterolemia with an MTP inhibitor |
US5962440A (en) * | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) * | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
KR19990044257A (ko) * | 1996-05-20 | 1999-06-25 | 디르크 반테 | 생체이용율이 개선된 항진균성 조성물 |
AU716151B2 (en) * | 1996-11-27 | 2000-02-17 | Pfizer Inc. | Apo B-secretion/MTP inhibitory amides |
JP2959765B2 (ja) * | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
JPH11246404A (ja) * | 1998-03-04 | 1999-09-14 | Taiho Yakuhin Kogyo Kk | 吸収を改善した医薬組成物 |
JP4027535B2 (ja) * | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
CA2362728C (en) * | 1999-03-24 | 2009-06-23 | Fmc Corporation | Improved aqueous solubility pharmaceutical formulations |
DE19933926A1 (de) * | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
DE19945594A1 (de) * | 1999-09-23 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
CA2324800A1 (en) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Use of apo b secretion/mtp inhibitors |
DE19963235A1 (de) * | 1999-12-27 | 2001-07-05 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10008159B4 (de) * | 2000-02-15 | 2005-08-18 | Rudy Dr. Susilo | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
CA2418490A1 (en) * | 2000-08-11 | 2002-02-21 | Eisai Co., Ltd. | Drug-containing solid dispersion having improved solubility |
US20040058903A1 (en) * | 2000-10-05 | 2004-03-25 | Hisashi Takasugi | Benzamide compounds as apo b secretion inhibitors |
US20040058956A1 (en) * | 2000-12-11 | 2004-03-25 | Yohko Akiyama | Pharmaceutical composition having an improved water solubility |
JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
JP3662566B2 (ja) * | 2002-02-28 | 2005-06-22 | 日本たばこ産業株式会社 | エステル化合物及びその医薬用途 |
SG165154A1 (en) * | 2002-02-28 | 2010-10-28 | Japan Tobacco Inc | Ester compound and medical use thereof |
CA2509688A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
EP1669345A4 (en) * | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
US20050181049A1 (en) * | 2003-11-19 | 2005-08-18 | Dong Liang C. | Composition and method for enhancing bioavailability |
JP2005239696A (ja) * | 2004-01-30 | 2005-09-08 | Daiichi Suntory Pharma Co Ltd | 無機物質を配合した医薬硬質カプセル剤 |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
-
2005
- 2005-10-20 AU AU2005297923A patent/AU2005297923B2/en not_active Ceased
- 2005-10-20 BR BRPI0516772-8A patent/BRPI0516772A/pt not_active IP Right Cessation
- 2005-10-20 KR KR1020077009257A patent/KR20070072888A/ko not_active Application Discontinuation
- 2005-10-20 CA CA2582767A patent/CA2582767C/en not_active Expired - Fee Related
- 2005-10-20 WO PCT/JP2005/019744 patent/WO2006046623A1/ja active Application Filing
- 2005-10-20 RU RU2007119378/15A patent/RU2375046C2/ru not_active IP Right Cessation
- 2005-10-20 MX MX2007004973A patent/MX2007004973A/es unknown
- 2005-10-20 EP EP05799275A patent/EP1806149A4/en not_active Withdrawn
- 2005-10-24 US US11/256,201 patent/US20060153913A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2582767C (en) | 2011-05-24 |
EP1806149A1 (en) | 2007-07-11 |
AU2005297923A1 (en) | 2006-05-04 |
EP1806149A4 (en) | 2012-12-05 |
RU2375046C2 (ru) | 2009-12-10 |
BRPI0516772A (pt) | 2008-09-23 |
US20060153913A1 (en) | 2006-07-13 |
KR20070072888A (ko) | 2007-07-06 |
AU2005297923B2 (en) | 2010-12-23 |
RU2007119378A (ru) | 2008-11-27 |
WO2006046623A1 (ja) | 2006-05-04 |
CA2582767A1 (en) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007004973A (es) | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. | |
EP1127570A3 (en) | Production process for polymeric micelle composition charged therein with drug | |
MX2011006771A (es) | Metodo de preparacion de una composicion de micelas polimericas que contienen un farmaco pobremente soluble en agua. | |
NO20074092L (no) | Tabletter for forbedret legemiddel dispersibilitet | |
NO20073339L (no) | Faste formuleringer av flytende biologisk aktive midler | |
HK1126709A1 (en) | A kind of hollow fiber porous membrane and its preparation method | |
EP1847260A3 (en) | Solid dispersion preparation | |
UA100866C2 (ru) | Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины | |
EP1588724A3 (en) | Composite material comprising fibrous organic material and fibrous calcium phosphate | |
DE69906269T2 (de) | Wässriges verfahren zur herstellung fester paroxetin-dispersionen | |
MXPA03006071A (es) | Preparaciones de ciclodextrina. | |
WO2007061938A3 (en) | Systems and methods for liquid dosing | |
CN104893362B (zh) | 一种表面疏水改性氧化钙的制备方法 | |
NO20052011L (no) | Oralt veterinaer medikament leveringssystem og/eller fortilsetningsmiddel leveringssystem, fremgangsmate for fremstilling og anvendelse derav | |
EP1847257A3 (en) | Solid preparation comprising enteric solid dispersion | |
WO2008053462B1 (en) | Fluid transfer device | |
JP2005509052A5 (es) | ||
CN102228423B (zh) | 托伐普坦口服固体药物组合物及其制备方法 | |
MX2010004291A (es) | Producto de dispersion solida de farmacos basados en n-aril urea. | |
Ingle et al. | Solubility enhancement of oral hypoglycemic agent by solid dispersion technique | |
RU2007145957A (ru) | Способ получения водорастворимых форм биологически активных веществ | |
CA2465918A1 (en) | Method for the production of particles | |
CN113856654A (zh) | 一种利用矿渣制备染料吸附剂的方法 | |
CN105052922A (zh) | 一种二氧化硅基农药缓释微囊制剂及其制备方法 | |
CA2669324A1 (en) | Method for preparing sustained release tablet |